BRPI0413081B8 - processo para produzir o cloridrato do composto imida - Google Patents

processo para produzir o cloridrato do composto imida

Info

Publication number
BRPI0413081B8
BRPI0413081B8 BRPI0413081A BRPI0413081A BRPI0413081B8 BR PI0413081 B8 BRPI0413081 B8 BR PI0413081B8 BR PI0413081 A BRPI0413081 A BR PI0413081A BR PI0413081 A BRPI0413081 A BR PI0413081A BR PI0413081 B8 BRPI0413081 B8 BR PI0413081B8
Authority
BR
Brazil
Prior art keywords
producing
imide compound
hydrochloride
enantiomer
formula
Prior art date
Application number
BRPI0413081A
Other languages
English (en)
Inventor
Oda Mayumi
Kakiya Yuzo
Original Assignee
Dainippon Sumitomo Pharma Co
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34100970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0413081(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dainippon Sumitomo Pharma Co, Sumitomo Dainippon Pharma Co Ltd filed Critical Dainippon Sumitomo Pharma Co
Publication of BRPI0413081A publication Critical patent/BRPI0413081A/pt
Publication of BRPI0413081B1 publication Critical patent/BRPI0413081B1/pt
Publication of BRPI0413081B8 publication Critical patent/BRPI0413081B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

"processo para a produção de composto imida". a presente invenção refere-se a um processo industrial excelente para produzir um cloridrato de composto imida. o processo para produzir um cloridrato de composto imida da fórmula (2): ou um enantiômero do mesmo, que compreende tratar um composto da fórmula (1): ou um enantiômero do mesmo com uma solução aquosa de ácido clorídrico em um solvente hidrofílico, e em seguida cristalizar o produto resultante.
BRPI0413081A 2003-07-29 2004-07-27 processo para produzir o cloridrato do composto imida BRPI0413081B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003-281860 2003-07-29
JP2003281860 2003-07-29
PCT/JP2004/011035 WO2005009999A1 (ja) 2003-07-29 2004-07-27 イミド化合物の製造方法

Publications (3)

Publication Number Publication Date
BRPI0413081A BRPI0413081A (pt) 2006-10-03
BRPI0413081B1 BRPI0413081B1 (pt) 2018-03-20
BRPI0413081B8 true BRPI0413081B8 (pt) 2021-05-25

Family

ID=34100970

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413081A BRPI0413081B8 (pt) 2003-07-29 2004-07-27 processo para produzir o cloridrato do composto imida

Country Status (12)

Country Link
US (2) USRE45573E1 (pt)
EP (1) EP1652848B1 (pt)
JP (1) JP4610485B2 (pt)
KR (1) KR101085806B1 (pt)
CN (1) CN100422178C (pt)
AT (1) ATE543817T1 (pt)
AU (1) AU2004259305B2 (pt)
BR (1) BRPI0413081B8 (pt)
CA (1) CA2538265C (pt)
DK (1) DK1652848T3 (pt)
ES (1) ES2378990T3 (pt)
WO (1) WO2005009999A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4866349B2 (ja) * 2005-06-13 2012-02-01 大日本住友製薬株式会社 可溶化型製剤
WO2008124030A1 (en) 2007-04-04 2008-10-16 Merck & Co., Inc. Therapeutic agents
WO2011093522A1 (en) * 2010-01-28 2011-08-04 Dainippon Sumitomo Pharma Co., Ltd. A cycloalkane derivative
DK2563790T3 (en) 2010-04-26 2016-10-24 Sumitomo Dainippon Pharma Co Ltd PROCESS FOR quaternary ammonium salt
JP5893616B2 (ja) 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
WO2012107890A2 (en) 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Crystalline forms of lurasidone hydrochloride
WO2012123858A1 (en) 2011-03-14 2012-09-20 Ranbaxy Laboratories Limited Amorphous lurasidone hydrochloride
WO2013014665A1 (en) 2011-07-28 2013-01-31 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of lurasidone and salts thereof
CZ304027B6 (cs) * 2011-08-18 2013-08-28 Farmak, A. S. Zpusob prípravy polymorfu (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyklohexylmethyl]-2,3-bicyklo[2.2.1]heptandikarboximidu hydrochloridu
CN102952064A (zh) * 2011-08-19 2013-03-06 天津药物研究院 一种医药中间体顺式-外-二环[2.2.1]庚烷-2.3-二甲酰亚胺的制备方法
WO2013030722A1 (en) 2011-08-26 2013-03-07 Ranbaxy Laboratories Limited Crystalline lurasidone hydrochloride
CN103130794B (zh) * 2011-12-02 2016-06-22 苏州二叶制药有限公司 卢拉西酮盐酸盐的晶体a的制备方法
CN103130795A (zh) * 2011-12-02 2013-06-05 苏州二叶制药有限公司 卢拉西酮盐酸盐的晶体a及其用途
WO2013121440A1 (en) 2012-02-13 2013-08-22 Cadila Healthcare Limited Process for preparing benzisothiazol-3-yl-peperazin-l-yl-methyl-cyclo hexyl-methanisoindol-1,3-dione and its intermediates
CN103360383B (zh) * 2012-04-11 2016-07-06 上海医药工业研究院 鲁拉西酮盐酸盐的晶型b及其制备方法
CN102746289B (zh) * 2012-04-28 2016-06-08 上海医药工业研究院 一种盐酸卢拉西酮的制备方法
WO2013190455A2 (en) * 2012-06-18 2013-12-27 Shasun Pharmaceuticals Limited Process for the preparation of lurasidone hydrochloride
CN102863437A (zh) * 2012-09-04 2013-01-09 济南百诺医药科技开发有限公司 一种鲁拉西酮的制备方法
WO2014064714A2 (en) * 2012-10-22 2014-05-01 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of lurasidone hydrochloride
CN102911170A (zh) * 2012-11-15 2013-02-06 苏州第壹制药有限公司 酰亚胺化合物盐酸盐的制备方法
CN104031041A (zh) * 2013-03-06 2014-09-10 江苏恩华药业股份有限公司 盐酸鲁拉西酮的新晶型及其制备方法
CN103539794A (zh) * 2013-10-17 2014-01-29 常州大学 一种盐酸鲁拉西酮的成盐方法
CZ306203B6 (cs) 2013-12-06 2016-09-29 Zentiva, K. S Způsob syntézy lurasidonu
US9790237B2 (en) 2014-06-16 2017-10-17 Johnson Matthey Public Limited Company Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates
WO2016059649A1 (en) * 2014-10-14 2016-04-21 Jubilant Generics Limited (Formerly Jubilant Life Sciences Division) An improved process for the preparation of lurasidone hydrochloride
SG11202008233WA (en) 2018-02-28 2020-09-29 Sumitomo Dainippon Pharma Co Ltd Aqueous suspension pharmaceutical preparation with controlled dissolution
SG11202008204QA (en) 2018-02-28 2020-09-29 Sumitomo Dainippon Pharma Co Ltd Aqueous suspension pharmaceutical preparation
CN113024535B (zh) 2019-12-24 2024-08-02 上海科胜药物研发有限公司 一种鲁拉西酮盐酸盐的制备方法
CN115950695B (zh) * 2021-10-09 2023-07-28 北京阳光诺和药物研究股份有限公司 一种制备鲁拉西酮基毒杂质的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS517440A (pt) * 1974-07-08 1976-01-21 Japan Storage Battery Co Ltd
JPS57197265A (en) * 1981-05-29 1982-12-03 Eisai Co Ltd Carboxylic acid imide derivative, its preparation and medicament containing the same
AU615966B2 (en) 1987-12-04 1991-10-17 Takeda Chemical Industries Ltd. Crystals of cephem hydrochloride
JP2800953B2 (ja) * 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5663381A (en) * 1995-04-21 1997-09-02 Hexal Pharmaceuticals, Inc. Process for preparing form 1 ranitidine hydrochloride
WO2001058835A1 (en) 2000-02-11 2001-08-16 Degussa Ag Resolution of dl-racemic mixtures
AU2001246861A1 (en) * 2000-04-10 2001-10-23 Sumitomo Pharmaceuticals Co. Ltd. Sustained release preparations
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション

Also Published As

Publication number Publication date
ES2378990T3 (es) 2012-04-19
KR101085806B1 (ko) 2011-11-22
US20060194970A1 (en) 2006-08-31
US7605260B2 (en) 2009-10-20
CN100422178C (zh) 2008-10-01
EP1652848A1 (en) 2006-05-03
USRE45573E1 (en) 2015-06-23
JP4610485B2 (ja) 2011-01-12
KR20060052840A (ko) 2006-05-19
CA2538265C (en) 2012-10-02
DK1652848T3 (da) 2012-02-27
WO2005009999A1 (ja) 2005-02-03
EP1652848A4 (en) 2009-04-15
JPWO2005009999A1 (ja) 2006-09-07
AU2004259305B2 (en) 2009-06-04
AU2004259305A1 (en) 2005-02-03
BRPI0413081B1 (pt) 2018-03-20
EP1652848B1 (en) 2012-02-01
BRPI0413081A (pt) 2006-10-03
CA2538265A1 (en) 2005-02-03
ATE543817T1 (de) 2012-02-15
CN1832946A (zh) 2006-09-13

Similar Documents

Publication Publication Date Title
BRPI0413081B8 (pt) processo para produzir o cloridrato do composto imida
NL300933I2 (nl) Letermovir
BRPI0406427B8 (pt) processo para a preparação de roflumilast
BRPI0407967A (pt) processo de uma etapa para a preparação de derivados anticonvulsivantes
BRPI0411713B8 (pt) compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização
BR0215396A (pt) Compostos, processo para a manufatura de compostos, composições farmacêuticas, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com "dpp-iv" e utilização dos compostos
BR0210424A (pt) Derivados de ácidos dicarboxìlicos aromáticos
BRPI0611350B8 (pt) formulação, seus usos e seu processo de fabricação,e artigo de fabricação
BR0307236A (pt) Processo para fabricação de compostos orgânicos
WO2008080891A3 (en) Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments
BR0301667A (pt) Processo para a preparação de polìmeros em emulsão com pureza elevada
BR0012631A (pt) Processo para a preparação de compostos de amina
BR0313795A (pt) Processo para a hidrogenação enantiosseletiva de aminoálcoois
IT1319234B1 (it) Processo di preparazione di gabapentina.
ATE541827T1 (de) Verfahren zur herstellung von adamantanaminen
BR0211291A (pt) Derivados de diamina, processo para produção dos derivados de diamina e fungicidas contendo os derivados de diamina como ingrediente ativo
BRPI0516595A (pt) processo para fabricar um composto, e, composto
BR0309753A (pt) Processo para a preparação de derivados de 6-alquilideno penem
BR0312593A (pt) Aciluréias substituìdas por uréia e uretano, processo para a sua produção e sua aplicação
BRPI0509263A (pt) processo para purificar mesotriona
BRPI0808570B8 (pt) processo para a preparação de inibidores de glyt-1
BR0115755A (pt) Processo para preparação de ácido 1-(aminometil) ciclohexano-acético
BRPI0415019A (pt) processo para a purificação da mesotriona
BRPI0411717A (pt) processo para a preparação de acilsulfamoibenzamidas
BR0215257A (pt) Compostos, processos para a manufatura de compostos, composições farmacêuticas, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com "osc" e utilização dos compostos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25D Requested change of name of applicant approved

Owner name: SUMITOMO DAINIPPON PHARMA CO., LTD. (JP)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/03/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/07/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2841 DE 17-06-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.